JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2003; 42:1933-1940, doi:10.1016/j.jacc.2003.07.016
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rauchhaus, M.
Right arrow Articles by Anker, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rauchhaus, M.
Right arrow Articles by Anker, S. D.

CLINICAL RESEARCH: HEART FAILURE

The relationship between cholesterol and survival in patients with chronic heart failure

Mathias Rauchhaus, MD*{dagger}, Andrew L. Clark, MD{ddagger},*, Wolfram Doehner, MD*, Constantinos Davos, MD, PhD*, Aidan Bolger, BSc*, Rakesh Sharma, BSc*, Andrew J. S. Coats, DM* and Stefan D. Anker, MD, PhD*§

* Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
{dagger} Klinik und Poliklinik für Innere Medizin III, Martin-Luther-Universität, Halle, Germany
{ddagger} Academic Cardiology, Castle Hill Hospital, Hull, United Kingdom
§ Franz-Volhard-Klinik (Charité, Campus Berlin-Buch) am Max-Delbrück Centrum für Molekulare Medizin, Berlin, Germany

Manuscript received April 9, 2003; revised manuscript received July 25, 2003, accepted July 28, 2003.

* Reprint requests and correspondence: Dr. Andrew L. Clark, Academic Cardiology, Castle Hill Hospital, Castle Road, Cottingham, Kingston-upon-Hull HU16 5JQ, United Kingdom.
A.L.Clark{at}hull.ac.uk

OBJECTIVES: We sought to describe the relationship between cholesterol and survival in patients with chronic heart failure (CHF).

BACKGROUND: Increasing lipoprotein levels are a cardiovascular risk factor. In patients with CHF, the prognostic value of endogenous lipoproteins is not fully clarified.

METHODS: A group of 114 patients with CHF recruited to a metabolic study was followed for a minimum of 12 months (derivation study). The results were applied to a second group of 303 unselected patients with CHF (validation study). The relationship between endogenous lipoproteins and survival was explored.

RESULTS: In the derivation study, survival at 12 months was 78% (95% confidence interval [CI] 70% to 86%) and 56% (95% CI 51% to 62%) at 36 months. Increasing total serum cholesterol was a predictor of survival (hazard ratio 0.64, 95% CI 0.48 to 0.86), independent of the etiology of CHF, age, left ventricular ejection fraction, and exercise capacity. Receiver-operating characteristic curves demonstrated a best cut-off value of ≤5.2 mmol/l (200.8 mg/dl) as being the best predictor of mortality at 12 months (sensitivity 80.0%, specificity 62.9%). In the validation population, one-year survival was 88% (95% CI 84 to 91%) and three-year survival was 68% (95% CI 63 to 73%). The chance of survival increased 25% for each mmol/l increment in total cholesterol. Survival rates above and below the cut-off value for cholesterol in patients with ischemic heart disease (n = 181) were 92% (95% CI 89 to 94) versus 75% (95% CI 64 to 85%) at one year and 72% (95% CI 67 to 76%) versus 50% (95% CI 43 to 56%) at three years.

CONCLUSIONS: In patients with CHF, lower serum total cholesterol is independently associated with a worse prognosis.

Abbreviations and Acronyms
  CHF = chronic heart failure
  CI = confidence interval
  HDL = high-density lipoprotein
  HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A
  HR = hazard ratio
  LDL = low-density lipoprotein
  LPS = lipopolysaccharide
  LVEF = left ventricular ejection fraction
  ROC = receiver-operating characteristics
  sTNF-R1 = soluble tumor necrosis factor receptor type 1
  VO2 = oxygen consumption
  VE/VCO2 slope = slope of the relationship between ventilation and carbon dioxide production




This article has been cited by other articles:


Home page
NEJMHome page
J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J. G.F. Cleland, J. H. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, et al.
Rosuvastatin in Older Patients with Systolic Heart Failure
N. Engl. J. Med., November 29, 2007; 357(22): 2248 - 2261.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C. E. Angermann, and S. Stork
Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure
Circulation, April 3, 2007; 115(13): 1754 - 1761.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. L. Coplan and M. Ramos
Is There a Statin Effect on Arrhythmia and Survival in Patients With Nonischemic Cardiomyopathy?
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1372 - 1372.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Heart Protection Study Collaborative Group,*
N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 311 - 319.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. von Haehling, W. Doehner, and S. D Anker
Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure
Cardiovasc Res, January 15, 2007; 73(2): 298 - 309.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. D. Kilpatrick, C. J. McAllister, C. P. Kovesdy, S. F. Derose, J. D. Kopple, and K. Kalantar-Zadeh
Association between Serum Lipids and Survival in Hemodialysis Patients and Impact of Race
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 293 - 303.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Bauersachs, K. Hiss, D. Fraccarollo, U. Laufs, and H. Ruetten
Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects
Cardiovasc Res, December 1, 2006; 72(3): 438 - 446.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. S. Go, W. Y. Lee, J. Yang, J. C. Lo, and J. H. Gurwitz
Statin therapy and risks for death and hospitalization in chronic heart failure.
JAMA, November 1, 2006; 296(17): 2105 - 2111.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C H Strey, J M Young, J H Lainchbury, C M Frampton, M G Nicholls, A M Richards, and R S Scott
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure
Heart, November 1, 2006; 92(11): 1603 - 1609.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. J. Goldberger, H. Subacius, A. Schaechter, A. Howard, R. Berger, A. Shalaby, J. Levine, A. H. Kadish, and for the DEFINITE Investigators
Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1228 - 1233.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen
Statins in the treatment of chronic heart failure: Biological and clinical considerations
Cardiovasc Res, August 1, 2006; 71(3): 443 - 454.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. C. Levy, D. Mozaffarian, D. T. Linker, S. C. Sutradhar, S. D. Anker, A. B. Cropp, I. Anand, A. Maggioni, P. Burton, M. D. Sullivan, et al.
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Circulation, March 21, 2006; 113(11): 1424 - 1433.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Christ, T. Klima, W. Grimm, H.-H. Mueller, and B. Maisch
Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy
Eur. Heart J., March 2, 2006; 27(6): 691 - 699.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
H. H. H. Feringa, J. J. Bax, O. Schouten, and D. Poldermans
Protecting the Heart with Cardiac Medication in Patients with Left Ventricular Dysfunction Undergoing Major Noncardiac Vascular Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2006; 10(1): 25 - 31.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. L. Karackattu, B. Trigatti, and M. Krieger
Hepatic Lipase Deficiency Delays Atherosclerosis, Myocardial Infarction, and Cardiac Dysfunction and Extends Lifespan in SR-BI/Apolipoprotein E Double Knockout Mice
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 548 - 554.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Sliwa, O. Forster, E. Libhaber, J. D. Fett, J. B. Sundstrom, D. Hilfiker-Kleiner, and A. A. Ansari
Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients
Eur. Heart J., February 2, 2006; 27(4): 441 - 446.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Ramasubbu and D. L. Mann
The Emerging Role of Statins in the Treatment of Heart Failure
J. Am. Coll. Cardiol., January 17, 2006; 47(2): 342 - 344.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. E. Bleske, J. M. Nicklas, R. L. Bard, R. D. Brook, P. A. Gurbel, K. P. Bliden, S. Rajagopalan, and B. Pitt
Neutral Effect on Markers of Heart Failure, Inflammation, Endothelial Activation and Function, and Vagal Tone After High-Dose HMG-CoA Reductase Inhibition in Non-Diabetic Patients With Non-Ischemic Cardiomyopathy and Average Low-Density Lipoprotein Level
J. Am. Coll. Cardiol., January 17, 2006; 47(2): 338 - 341.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
K. Kalantar-Zadeh, S. D. Anker, A. J. S. Coats, T. B. Horwich, and G. C. Fonarow
Obesity Paradox as a Component of Reverse Epidemiology in Heart Failure
Arch Intern Med, August 8, 2005; 165(15): 1797 - 1797.
[Full Text] [PDF]


Home page
CirculationHome page
M. R. Zile
Treating Diastolic Heart Failure With Statins: "Phat" Chance for Pleiotropic Benefits
Circulation, July 19, 2005; 112(3): 300 - 303.
[Full Text] [PDF]


Home page
CirculationHome page
H. Fukuta, D. C. Sane, S. Brucks, and W. C. Little
Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report
Circulation, July 19, 2005; 112(3): 357 - 363.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, S. Schulz, C. Manes, D. Fischer, K. de Groot, D. Fliser, et al.
Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans
Circulation, May 10, 2005; 111(18): 2356 - 2363.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. G. Ray, Y. Gong, K. Sykora, and J. V. Tu
Statin Use and Survival Outcomes in Elderly Patients With Heart Failure
Arch Intern Med, January 10, 2005; 165(1): 62 - 67.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S von Haehling and S D Anker
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
Heart, January 1, 2005; 91(1): 1 - 2.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
High Cholesterol Linked with Better Survival in Heart Failure
Journal Watch Cardiology, March 5, 2004; 2004(305): 4 - 4.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.